PolyPhotonix Limited Announces Strategic Alliance with Prevail InfoWorks, Inc. and Prevail Partners, LLC

PolyPhotonix Limited, developer of a patented noninvasive treatment for diabetic retinopathy, entered a global strategic alliance with Prevail InfoWorks, Inc. (“InfoWorks”) to lead management of FDA regulated human clinical trials of PolyPhotonix’s Noctura 400 Sleep Mask.

The Noctura 400 Sleep Mask has the potential to treat and prevent diabetic retinopathy, a condition of diabetic patients that can lead to blindness. Diabetic retinopathy represents a significant burden of disease for both patients and healthcare systems globally and is a significant cause of blindness in the working age population.

InfoWorks will deploy its patented capabilities and technology for achieving the highest quality data in the shortest possible time during clinical trials. In addition, Prevail Partners, LLC, an affiliate of InfoWorks, has agreed to invest significantly in PolyPhotonix upon the commencement of the FDA clinical trial as lead investor in a Series A investment round. Current investors include the UK Future Fund and Revere Capital Advisors LLC.

PolyPhotonix’s relationship with InfoWorks, assisted by the commitment of Prevail Partners, will expedite the progression of its FDA trial for the Noctura 400 Sleep Mask. PolyPhotonix, InfoWorks and Prevail Partners anticipate that this relationship will benefit the advancement of other indications from PolyPhotonix’s biotechnology pipeline.

PolyPhotonix (www.polyphotonix.com) is a bio-photonic research and development company that designs, develops, and manufactures noninvasive photonic-based medical devices focused on light therapy treatments for macular eye disease. PolyPhotonix’s Noctura 400 Sleep Mask is an innovative, noninvasive, and monitored home care treatment developed to prevent and treat diabetic retinopathy.

Prevail Partners (www.prevailpartners.com) is an investment fund focused on life sciences companies. The fund is designed to take advantage of the attractive returns possible in promising scientific advances in the life science fields of therapeutics, preventive treatments, medical devices and diagnostics. A uniquely favourable feature of the fund is that Prevail InfoWorks applies proprietary technologies and services to equip companies in which the fund invests, giving investors and strategic licensing partners the comfort that the clinical trials have a higher likelihood of success.

For over a decade, InfoWorks, (www.prevailinfoworks.com) has been dedicated to providing biotech, pharmaceutical, medical device and diagnostics companies with the most innovative and complete technology and service solutions for their clinical development. The company delivers unique products and services that accelerate and de-risk drug development and the clinical regulatory process more rapidly and cost effectively, including through real-time actionable intelligence of evolving topline trends and metrics to patient-specific data derived from aggregating all clinical, diagnostic, operational and project accounting data.

News source: PolyPhotonix.

POLYPHOTONIX

Other News

SiP Packaging Engineer

Radiation tech specialist to see half year revenues rise 45%

Kromek secures £5m bio-detection contract

Kromek seals $1.3m deal for ‘dirty bomb’ detectors with American customer

County Durham MedTech firm’s treatment could save the NHS over £180m per year

Science Park Manager – NETPark

Follow NETPark On Social Media

Keep up to date with the latest NETPark news and events.

NETPark Logo

The North East Technology Park provides a dynamic and supportive environment to accelerate the growth of ambitious, innovative, high tech companies into global markets. NETPark encourages collaborative multidisciplinary links, driving innovation, enterprise and economic prosperity.
We provide companies with access to a focused and international community where talent flourishes, ideas are generated and businesses have the support and resources to compete with the best in the world.

NETPark North East Technology Park

NETPark, North East Technology Park,
Sedgefield, County Durham TS21 3FD

Call Us: (+44) 01740 625250
Email: enquiries@northeasttechnologypark.com
Web: northeasttechnologypark.com

CPI has developed a specialist offering to support SMEs looking to develop their printable electronics applications and our partnership with Business Durham has been instrumental in attracting several SMEs to locate here in the region.

Dr Jon Helliwell, - Director of Printable Electronics, CPI

It fits perfectly for us that we’re surrounded by like-minded companies at NETPark. There are a number of highly skilled people in the area who can help us grow our business. The facilities and services offered by NETPark are first class, they make office life simple and engaging.

Stuart Wilson, - CEO, Ascarii

The proximity to the universities and the infrastructure are very important factors. Ultimately having a presence in Europe is very valuable to us and we intend to stay at NETPark for many years to come.

Dr Arnab Basu, - CEO, Kromek

Access to quality facilities was one of the main drivers for deciding to locate the business at the NETPark. We have been able to use this as a launch pad to link into support from CPI and world-class expertise from Durham University.

Steve Clements, - Managing Director, aXenic

The quality of the facilities at NETPark and the attitude of staff is first class. It has a really dynamic, innovative atmosphere.

Dr Neil Loxley, - Chief executive, IBEX

We initially came because of the printable electronics centre but access to a highly skilled semi conductor workforce in the North East has been a key factor in us staying and growing here, as well as the value for money office space and the access to funding.

Ken Williamson, - COO, PragmatIC Printing
2022-01-10T14:05:00+00:00
Go to Top